Hanall Biopharma Co., Ltd. (KRX:009420)

Hanall Biopharma Statistics

Total Valuation

KRX:009420 has a market cap or net worth of KRW 2.91 trillion. The enterprise value is 2.92 trillion.

Market Cap	2.91T
Enterprise Value	2.92T

Important Dates

The next estimated earnings date is Wednesday, May 13, 2026.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

KRX:009420 has 50.78 million shares outstanding. The number of shares has increased by 1.73% in one year.

Current Share Class	50.78M
Shares Outstanding	50.78M
Shares Change (YoY)	+1.73%
Shares Change (QoQ)	+0.68%
Owned by Insiders (%)	0.40%
Owned by Institutions (%)	12.75%
Float	34.46M

Valuation Ratios

PE Ratio	n/a
Forward PE	2,843.67
PS Ratio	18.78
PB Ratio	18.03
P/TBV Ratio	18.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-525.61
EV / Sales	18.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-888.57

Financial Position

The company has a current ratio of 1.91, with a Debt / Equity ratio of 0.20.

Current Ratio	1.91
Quick Ratio	0.99
Debt / Equity	0.20
Debt / EBITDA	16.37
Debt / FCF	-9.71
Interest Coverage	-11.31

Financial Efficiency

Return on equity (ROE) is -3.37% and return on invested capital (ROIC) is -1.02%.

Return on Equity (ROE)	-3.37%
Return on Assets (ROA)	-0.46%
Return on Invested Capital (ROIC)	-1.02%
Return on Capital Employed (ROCE)	-0.89%
Weighted Average Cost of Capital (WACC)	9.11%
Revenue Per Employee	510.48M
Profits Per Employee	-18.29M
Employee Count	304
Asset Turnover	0.71
Inventory Turnover	1.96

Taxes

Income Tax	-620.72M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +60.84% in the last 52 weeks. The beta is 0.90, so KRX:009420's price volatility has been similar to the market average.

Beta (5Y)	0.90
52-Week Price Change	+60.84%
50-Day Moving Average	52,922.00
200-Day Moving Average	38,513.75
Relative Strength Index (RSI)	53.82
Average Volume (20 Days)	435,102

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KRX:009420 had revenue of KRW 155.18 billion and -5.56 billion in losses. Loss per share was -109.00.

Revenue	155.18B
Gross Profit	80.77B
Operating Income	-1.61B
Pretax Income	-6.18B
Net Income	-5.56B
EBITDA	1.95B
EBIT	-1.61B
Loss Per Share	-109.00

Balance Sheet

The company has 24.74 billion in cash and 31.92 billion in debt, with a net cash position of -7.17 billion or -141.27 per share.

Cash & Cash Equivalents	24.74B
Total Debt	31.92B
Net Cash	-7.17B
Net Cash Per Share	-141.27
Equity (Book Value)	161.68B
Book Value Per Share	3,183.90
Working Capital	40.44B

Cash Flow

In the last 12 months, operating cash flow was -2.34 billion and capital expenditures -948.00 million, giving a free cash flow of -3.29 billion.

Operating Cash Flow	-2.34B
Capital Expenditures	-948.00M
Free Cash Flow	-3.29B
FCF Per Share	-64.76

Margins

Gross margin is 52.05%, with operating and profit margins of -1.04% and -3.58%.

Gross Margin	52.05%
Operating Margin	-1.04%
Pretax Margin	-3.98%
Profit Margin	-3.58%
EBITDA Margin	1.26%
EBIT Margin	-1.04%
FCF Margin	n/a

Dividends & Yields

KRX:009420 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.73%
Shareholder Yield	-1.73%
Earnings Yield	-0.19%
FCF Yield	-0.11%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 28, 2006. It was a forward split with a ratio of 10.

Last Split Date	Apr 28, 2006
Split Type	Forward
Split Ratio	10

Scores

KRX:009420 has an Altman Z-Score of 17.12 and a Piotroski F-Score of 2.

Altman Z-Score	17.12
Piotroski F-Score	2